Surgical-site & mesh infections
Surgical-site infections (SSIs) involving implanted mesh, vascular grafts, or other prosthetic material are a major driver of surgical morbidity, and Staphylococcus aureus (including MRSA) is the dominant pathogen. Once S. aureus colonizes a foreign body it forms a recalcitrant biofilm on the mesh surface that shields it from antibiotics and host immunity, so cure frequently requires surgical explantation of the device with high cost and morbidity. Bacteriophages are attractive here because they self-amplify at the site of infection, actively penetrate and disrupt biofilm, and are intrinsically active against multidrug-resistant strains that defeat conventional antibiotics. As a strain-specific, device-sparing adjunct they offer the prospect of clearing mesh/graft infection without removing the implant.
How phages act here
Mechanism
Lytic phages bind S. aureus surface receptors (e.g., wall teichoic acid, peptidoglycan moieties), inject their genome, replicate, and lyse the cell, then propagate locally as long as host bacteria persist. Because this is strain-specific, treatment typically uses a multi-phage cocktail (or pre-treatment susceptibility/"phagogram" matching) to broaden coverage across S. aureus lineages and limit resistance. Critically for mesh and prosthetic infections, many staphylococcal phages and their depolymerase/endolysin enzymes degrade biofilm extracellular matrix and reach metabolically dormant persister cells that antibiotics miss, and phages are usually combined with antibiotics to exploit phage-antibiotic synergy (sub-inhibitory antibiotics can enhance phage replication and suppress emergence of phage-resistant mutants). Engineered approaches (CRISPR-armed phages and recombinant lysins such as CHAPSH3b) are an active research frontier aimed at sharpening antibiofilm activity, though clinical mesh-infection use to date relies on natural lytic cocktails delivered topically/intravenously alongside standard care.
Where it stands
Current evidence
As of 2026 the evidence is early-stage but accelerating and now includes a registered trial aimed squarely at this indication. DUOFAG (NCT06319235; sponsor MB Pharma), a Phase 1/2 randomized, blinded, placebo-controlled trial, is enrolling ~52 patients with surgical-site infections caused by S. aureus and/or P. aeruginosa, applying a topical two-phage-against-S. aureus cocktail to the wound twice daily for up to two weeks. Broader S. aureus phage development is more advanced systemically: Armata Pharmaceuticals' AP-SA02 IV phage cocktail completed a Phase 2a randomized, double-blind, placebo-controlled trial in complicated S. aureus bacteremia (reported October 2025) showing a Day-12 clinical-response rate of 88% with AP-SA02 plus best-available antibiotics versus 58% with placebo, with no relapse in the phage arm and a favorable safety profile. For device/graft-associated S. aureus SSIs specifically, the human data remain at the level of compassionate-use case series — most notably Rubalskii et al. (2020), in which 7 of 8 cardiothoracic-surgery patients with infections of vascular grafts, implanted devices, and surgical wounds (several due to S. aureus) achieved bacterial eradication when phages were added to antibiotics. A 2025 systematic review confirms consistent antibiofilm efficacy of staphylococcal phages in vitro/in vivo but emphasizes that dosing, administration, and phage-antibiotic synergy still need standardization before routine clinical use.
Evidence confidence: medium
The data
Key studies & trials
- MB Pharma. Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG (a bacteriophage cocktail against Staphylococcus aureus and Pseudomonas aeruginosa) in Surgical Site Infections. ClinicalTrials.gov identifier NCT06319235 (Phase 1/2, registered 2024). ↗
- Rubalskii E, Ruemke S, Salmoukas C, Boyle EC, Warnecke G, Tudorache I, Shrestha M, Schmitto JD, Martens A, Rojas SV, Ziesing S, Bochkareva S, Kuehn C, Haverich A. Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery. Antibiotics (Basel). 2020;9(5):232. ↗
- Mobarezi Z, Esfandiari AH, Abolbashari S, Meshkat Z. Efficacy of phage therapy in controlling staphylococcal biofilms: a systematic review. European Journal of Medical Research. 2025;30(1):605. ↗
- Armata Pharmaceuticals. A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous Bacteriophage Cocktail (AP-SA02) vs Placebo plus Best Available Antibiotic Therapy in Patients with Complicated Staphylococcus aureus Bacteremia. Open Forum Infectious Diseases / IDWeek 2025 (abstract 549), published 2026. ↗
Who is working on it
Programs & centers
The possibility
Within the next few years, a surgeon facing an infected mesh or graft may order a rapid phagogram, then irrigate the implant with a matched S. aureus phage cocktail at closure — clearing biofilm and saving the device instead of explanting it. As cocktails become standardized and paired synergistically with antibiotics, phages could shift mesh and prosthetic SSIs from an implant-removal problem to a treatable, implant-sparing one. Engineered and lysin-armed phages further raise the possibility of phage-coated meshes that resist S. aureus colonization from the moment they are placed.